BioLife Solutions CTO acquires 45,838 and 48,232 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BioLife Solutions Chief Technology Officer Sean Werner reported acquiring 45,838 shares and 48,232 shares under restricted-stock awards on October 6, 2026. Both awards vested immediately before the merger effective time at approximately 200% of the number of shares granted, based on BioLife’s total shareholder return compared with certain peers over separate performance periods. Werner also reported 71,226 shares withheld for tax obligations at a reported price of $38.61 per share, and the disposition of 69,979 shares in connection with the consummation of the merger with Repligen Corporation. Under the merger terms, each BioLife common share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F2 | 45,838 | -- | -- |
| Grant/Award | Common Stock F3 | 48,232 | -- | -- |
| Tax Withholding | Common Stock F4 | 71,226 | $38.61 | $2.75M |
| Disposition | Common Stock F1 | 69,979 | -- | -- |
Footnotes (4)
- F1. Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
- F2. The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
- F3. The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
- F4. Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Key Figures
Key Terms
market-based restricted stock award financial
First Merger Effective Time technical
tax withholding obligations financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did Sean Werner’s BLFS restricted-stock awards vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.